Clinical Trial Transparency Declaration

Genmab is committed to transparency of clinical trial research. We recognize the scientific and ethical value of sharing clinical trial information in a non-biased and timely manner to benefit diverse audiences. Transparency in clinical trials helps patients and health-care providers to make well-informed decisions about patients’ health. Rooted in science and inspired by patients, we are committed to our vision to fundamentally transforming the lives of people with cancer and other serious diseases.

Disclosure of clinical trial information

Genmab complies with applicable laws and requirements for clinical trial disclosure. Our clinical trial information is shared in a way that protects intellectual property and privacy in accordance with global and national data privacy laws.

Our commitments apply to all Genmab-sponsored interventional clinical trials, Phase 1 and beyond, conducted worldwide. To the extent applicable, our commitments also apply to Genmab-sponsored non-interventional clinical studies and expanded access programs.

- Genmab registers clinical trial protocols and posts aggregated clinical trial results, irrespective of outcome, on publicly accessible study registries worldwide. Our ambition is to provide consistent information across registries, meeting the different needs and expectations of patients, the research community, and society.
  - Registration
    - We prospectively register all clinical trials on ClinicalTrials.gov irrespective of where the trial is conducted, before the first trial participant provides informed consent.
    - If applicable, we also make public clinical trial protocol information via the EU Clinical Trials Register or EU CTIS and on national registries.
  - Results disclosure
    - We provide technical results from clinical trials in formats and timeframes as stipulated by laws and regulations.
    - We post non-promotional summaries of key clinical trial results that are understandable for non-scientists via EU CTIS and other platforms where else required.

- Upon request by external researchers and healthcare providers, clinical-regulatory documents that support or are associated with our marketed products might be provided. No personal data will be shared and any information which is considered Genmab confidential information will be redacted before sharing such documents. Contractual agreements with our collaboration partners may restrict the sharing of information.

To learn more about our clinical trials (partner-sponsored trials being excluded):

Genmab’s ongoing clinical trials
Genmab’s past clinical trials
Journal publications

Genmab is committed to publication of clinical trial results in peer-reviewed, scientific literature in alignment with PhRMA/EFPIA principles on clinical data sharing regardless of outcome. At a minimum, results from all Phase 3 clinical trials and any clinical trial results of significant medical importance including discontinued assets should be submitted for publication within 18 months of study completion.

All non-clinical research including non-interventional studies must be published if it addresses a scientific gap and/or if the findings are of medical importance.

Development of Genmab-sponsored scientific publications will be based on publication principles and industry standards. Sources of funding, institutional affiliations and conflicts of interest must be declared in the publication, if applicable.